Biomarkers of Leucine‐Rich Repeat Kinase 2 ( LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy

Key Points

• The aim is to explore biomarkers related to LRRK2 and lysosomal dysfunction in progressive supranuclear palsy (PSP).
• Analyzed biochemical markers of lysosomal function in PSP patients.
• Conducted genetic stratification to assess patient eligibility for LRRK2-targeting therapies.
• Biochemical evidence of lysosomal dysfunction is present in PSP patients.
• Genetic markers may help identify PSP patients who could benefit from specific therapies targeting LRRK2.